Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: Superiority of molecular genetics

British Journal of Haematology

Volumn 137, Issue 6, 2007, Pages 530-536

  Shaughnessy Jr , John D ^a   Haessler, Jeffrey ^b   Van Rhee, Frits ^a   Anaissie, Elias ^a   Pineda Roman, Mauricio ^a   Cottler Fox, Michele ^a   Hollmig, Klaus ^a   Zangari, Maurizio ^a   Mohiuddin, Abid ^a   Alsayed, Yazan ^a   Grazziutti, Monica ^a   Epstein, Joshua ^a   Crowley, John ^b   Barlogie, Bart ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Gene expression profiling; Molecular genetics; Myeloma; Prognosis

Indexed keywords

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CHROMOSOME 13Q; CHROMOSOME 1Q; CHROMOSOME DELETION 13; CONTROLLED STUDY; CYTOGENETICS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENETIC MODEL; GENETIC PARAMETERS; GENETIC RISK; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MALE; MOLECULAR GENETICS; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE GENETICS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; STANDARD; STATISTICAL SIGNIFICANCE; SURVIVAL TIME; TRANSPLANTATION;

ADULT; AGED; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 1; CYTOGENETIC ANALYSIS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIERS ESTIMATE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MODELS, STATISTICAL; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; PROGNOSIS; RISK FACTORS;

EID: 34249275302     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2007.06586.x     Document Type: Article

References (20)

1. Barlogie, B., Smallwood, L., Smith, T. Alexanian, R. (1989) High serum levels of lactic dehydrogenase identify a high-grade lymphoma-like myeloma. Annals of Internal Medicine, 110, 521 525.
2. Barlogie, B., Tricot, G., van Rhee, F., Angtuaco, E., Walker, R., Epstein, J., Shaughnessy, J., Jagannath, S., Bolejack, V., Gurley, J., Hoering, A., Vesole, D., Desikan, R., Siegel, D., Mehta, J., Singhal, S., Munshi, N., Dhodpkar, M., Jenkins, B., Attal, M., Harousseau, J-L. Crowley, J. (2006a) Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. British Journal of Haematology, 135, 158 164.
3. Barlogie, B., Tricot, G., Rasmussen, R., Anaissie, E., van Rhee, F., Zangari, M., Fassas, A., Hollmig, K., Pineda-Roman, M., Shaughnessy, J., Epstein, J. Crowley, J. (2006b) Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies. Blood, 107, 2633 2638.
4. Barlogie, B., Tricot, G., Anaissie, E., Shaughnessy, J., Rasmussen, E., van Rhee, F., Fassas, A., Zangari, M., Hollmig, K., Pineda-Roman, M., Lee, C., Talamo, G., Thertulien, R., Kiwan, E., Krishna, S., Fox, M. Crowley, J. (2006c) Thalidomide and Hematopoietic-cell transplantation for multiple myeloma. New England Journal of Medicine, 354, 1021 1030.
5. Bataille, R., Boccadoro, M., Klein, B., Durie, B. Pileri, A. (1992) C-reactive protein and B-2 microglobulin produce a simple and powerful myeloma staging system. Blood, 80, 733 737.
6. Blade, J., Samson, D., Reece, D., Reece, D., Apperley, J., Bjorkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S. Vesole, D. (1998) Criteria for evaluating response in patients with multiple myeloma treated by high-dose therapy and hematopoietic stem cell transplantation. British Journal of Haematology, 102, 1115 1123.
7. Cox, D.R. (1972) Regression tables and life tables. Journal of the Royal Statistical Society: Series B, 34, 187 202.
8. Desikan, R., Barlogie, B., Sawyer, J., Ayers, D., Tricot, G., Badros, A., Zangari, M., Munshi, N., Anaissie, E., Spoon, D., Siegel, D., Jagannath, D., Vesole, D., Epstein, J., Shaughnessy, J., Fassas, A., Lim, S., Roberson, P. Crowley, J. (2000) Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood, 95, 4008 4010.
9. Dimopoulos, M., Barlogie, B., Smith, T.L. Alexanian, R. (1991) High serum lactic dehydrogenase as a marker of drug resistance in multiple myeloma. Annals of Internal Medicine, 115, 931 935.
10. Durie, B.G. Salmon, S.E. (1975) A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer, 36, 842 854.
11. Greipp, P., San Miguel, J., Durie, B., Crowley, J., Barlogie, B., Blade, J., Boccadoro, M., Child, A., Avet-Loiseau, H., Kyle, R., Lahuerta, J., Ludwig, H., Morgan, G., Powles, R., Shimizu, K., Shustik, C., Sonneveld, P., Tosi, P., Turesson, I. Westin, J. (2005) International Staging System for Multiple Myeloma. Journal of Clinical Oncology, 23, 3412 3420.
12. Hanamura, I., Stewart, J.P., Huang, Y., Zhan, F., Santra, M., Sawyer, J.R., Hollmig, K., Zangari, M., Pineda-Roman, M., van Rhee, F., Cavallo, F., Burington, B., Crowley, J., Tricot, G., Barlogie, B., Shaughnessy, Jr. J.D. (2006) Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood, 108, 1724 1732.
13. Jacobson, J., Barlogie, B., Shaughnessy, J., Drach, J., Tricot, G., Fassas, A., Zangari, M., Giroux, D., Crowley, J., Hough, A. Sawyer, J. (2003) MDS-type abnormalities within myeloma signature karyotype (MM-MDS): only 13% 1-year survival despite tandem transplants. British Journal of Haematology, 122, 430 440.
14. Kaplan, E.L. Meier, P. (1958) Nonparametric estimation from incomplete observations. Journal of American Statistical Association, 53, 457 481.
15. Shaughnessy, J., Tian, E., Sawyer, J., Bumm, K., Landes, R., Badros, A., Morris, C., Tricot, G., Epstein, J. Barlogie, B. (2000) High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH. Blood, 96, 1505 1511.
16. Shaughnessy, J., Zhan, F., Burington, B., Huang, Y., Colla, S., Hanamura, I., Stewart, J., Kordsmeier, B., Randolph, C., Williams, D.R., Ziao, Y., Xu, H., Epstein, J., Anaissie, E., Krishna, S., Cottler-Fox, M., Hollmig, K., Mohiuddin, A., Pineda-Roman, M., Tricot, G., van Rhee, F., Sawyer, J., Alsayed, Y., Walker, R., Zangari, M., Crowley, J. Barlogie, B. (2006) A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood, 109, 2276 2284.
17. Walker, R., Barlogie, B., Haessler, J., Tricot, G., Anaissie, E., Shaughnessy, J., Epstein, J., Van Hemert, R., Erdem, E., Hoering, A., Crowley, J., Ferris, E., Hollmig, K., van Rhee, F., Zangari, M., Pineda-Roman, M., Mohiuddin, A., Yaccoby, S., Sawyer, J. Angtuaco, E.J. (2007) Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. JCO, 25, 1121 1128.
18. Wilcoxon, F. (1945) Individual comparisons by ranking methods. Biometrics, 1, 80 83.
19. Zhan, F., Hardin, J., Kordsmeier, B., Bumm, K., Zheng, M., Tian, E., Sanderson, R., Yang, Y., Wilson, C., Zangari, M., Anaissie, E., Morris, C., Muwalla, F., van Rhee, F., Fasas, A., Crowley, J., Tricot, G., Barlogie, B. Shaughnessy, S. (2002) Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance and normal bone marrow plasma cells. Blood, 99, 1745 1757.
20. Zhan, F., Huang, Y., Colla, S., Stewart, J.P., Hanamura, I., Gupta, S., Epstein, J., Yaccoby, S., Sawyer, J., Burington, B., Anaissie, E., Hollmig, K., Pineda-Roman, M., Tricot, G., van Rhee, F., Walker, R., Zangari, M., Crowley, J., Barlogie, B., Shaughnessy, Jr. J.D. (2006) The molecular classification of multiple myeloma. Blood, 108, 2020 2028.